InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

Current share price for MYX : $2.450 0.04 (1.61%)+

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$201 Mayne Pharma recipient of A$4m Government Grant 4 Aug 2015 2:26PM $1.210 $2.450 risen by 102.48%
$201 Appendix 3B 4 Aug 2015 9:54AM $1.200 $2.450 risen by 104.17%
$201 Appendix 3B and lapse of employee options 13 Jul 2015 2:58PM $1.130 $2.450 risen by 116.81%
$201 Mayne Pharma successfully completes US$125m debt financing 25 Jun 2015 9:21AM $1.055 $2.450 risen by 132.23%
$201 Appendix 3B 23 Jun 2015 8:51AM $1.055 $2.450 risen by 132.23%
$201 Change of registered office address 22 Jun 2015 10:36AM $1.060 $2.450 risen by 131.13%
$201 Appendix 3B 28 May 2015 12:33PM $1.120 $2.450 risen by 118.75%
$201 Appendix 3B 18 May 2015 1:07PM $1.145 $2.450 risen by 113.97%
$201 New equity investment in Hedgepath Pharmaceuticals 18 May 2015 8:50AM $1.150 $2.450 risen by 113.04%
$201 Appendix 3B 6 May 2015 10:17AM $1.140 $2.450 risen by 114.91%
$201 US Oxycodone franchise restructure and Doryx re-launch 4 May 2015 9:14AM $1.110 $2.450 risen by 120.72%
$201 Pfizer withdraws US Tikosyn Litigation against Mayne Pharma 25 Feb 2015 9:18AM $0.880 $2.450 risen by 178.41%
$201 Completion institutional entitlement offer and placement 12 Feb 2015 9:16AM $0.700 $2.450 risen by 250%
$201 Trading Halt 10 Feb 2015 8:56AM $0.700 $2.450 risen by 250%
$201 Mayne Pharma announces US Paragraph IV Challenge 18 Nov 2014 9:30AM $0.785 $2.450 risen by 212.10%
$201 2014 Appendix 4E & Annual Report 27 Aug 2014 8:45AM $0.840 $2.450 risen by 191.67%
$201 Mayne Pharma out-licenses IP to Hedgepath Pharmaceuticals 25 Jun 2014 11:05AM $0.875 $2.450 risen by 180%
$201 Half Yearly Report and Accounts 26 Feb 2014 12:06PM $0.880 $2.450 risen by 178.41%
$201 Completion of placement 13 Feb 2014 8:41AM $0.865 $2.450 risen by 183.24%
$201 Mayne Pharma announces acquisition of LORCET & ESGIC 12 Feb 2014 9:11AM $0.790 $2.450 risen by 210.13%
$201 Trading Halt 12 Feb 2014 8:54AM $0.790 $2.450 risen by 210.13%
$201 Mayne Pharma results and product update 6 Feb 2014 9:03AM $0.790 $2.450 risen by 210.13%
$201 MYX announces US agreement for Itraconazole in Cancer 11 Sep 2013 9:26AM $0.620 $2.450 risen by 295.16%
$201 2013 Full Year Results Appendix 4E 27 Aug 2013 1:10PM $0.560 $2.450 risen by 337.50%
$201 Mayne Pharma Signs European SUBACAP Distribution Agreements 9 Aug 2013 8:37AM $0.580 $2.450 risen by 322.41%

851 - 875 of 908 results

Page 35 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.